Recent Updates
Recently added Catalysts
PRCT Positive Sentiment Score: 75/100

PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference

Key Takeaway: PROCEPT BioRobotics announced its participation in two upcoming conferences, the 2024 Leerink Partners Healthcare Crossroads Conference and the 44th Annual William Blair Growth Stock Conference. Scheduled presentations will offer insights into the company's advancements in surgical robotics, particularly in urology. Notably, the AquaBeam Robotic System, designed for treating benign prostatic hyperplasia, will be highlighted. Webcasts of the presentations will be available for investors to access online after the events.

Market Sentiment Analysis

POSITIVE FACTORS

  • PROCEPT BioRobotics is presenting at two high-profile conferences, indicating robust interest in the company's advancements.
  • The AquaBeam Robotic System aims to transform patient care in urology, showcasing innovation in medical technology.
  • The company has a strong foundation of clinical evidence supporting its Aquablation therapy.

Full Press Release Details

SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at the upcoming 44th Annual William Blair Growth Stock Conference in Chicago. Management is scheduled to present on Tuesday, June 4 at 5:00 p.m. Eastern Time.
A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
VP, Investor Relations and Business Operations

Frequently Asked Questions

When and where will PROCEPT BioRobotics present?

PROCEPT BioRobotics will present at the 2024 Leerink Partners Healthcare Crossroads Conference on May 29 and at the William Blair Growth Stock Conference on June 4.

How can I watch the PROCEPT BioRobotics presentations?

You can view the live webcast and archived recordings on the 'Investors' section of their website.

What is the AquaBeam Robotic System used for?

The AquaBeam Robotic System is designed for minimally invasive surgery to treat benign prostatic hyperplasia (BPH).

What does BPH stand for in medical terms?

BPH stands for benign prostatic hyperplasia, which is a common prostate condition affecting many men.

How many clinical studies support Aquablation therapy?

Aquablation therapy is supported by nine clinical studies and over 150 peer-reviewed publications.

Last updated: May 13, 2024